Send to:

Choose Destination
See comment in PubMed Commons below
J Nephropathol. 2013 Apr;2(2):114-21. doi: 10.12860/JNP.2013.19. Epub 2013 Apr 1.

The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome.

Author information

  • 1Tokyo Medical and Dental University Graduate School of Health Care Sciences, Tokyo, Japan.
  • 2Department of Molecular Target Medicine Screening, Aichi Medical University School of Medicine, Aichi, Japan.
  • 3Department of Environmental Health, National Institute of Public Health, Saitama, Japan.



β2-glycoprotein I (β2GPI)-dependent antiphospholipid antibodies (aPLs) are considered to play a pivotal pathogenic role in antiphospholipid syndrome (APS) by inducing the expression of tissue factor, inflammatory cytokines, and chemokines, most of which are dependent upon the NF-κB pathway. Therefore, the NF-κB is regarded as a promising target for the development of a novel therapeutic strategy. However, progress has been limited owing to the fact that there are no widely-used in vivo models, or highly specific inhibitors.


This study aimed to test the effects of an NF-κB-specific inhibitor, DHMEQ, in preventing thrombus formation using an original mouse model of APS.


Specificity of a monoclonal aPL WB-6 was examined by ELISA. WB-6 was injected into normal BALB/c mice with or without DHMEQ treatment. A pulse laser was radiated to a cutaneous vein in the window of a dorsal skinfold chamber attached to the mouse and thrombus formation was observed and recorded under a microscope.


WB-6 bound preferentially to the caldiolipin (CL)-β2GPI complex rather than to CL alone, or β2GPI alone. WB-6, but not isotype-matched control antibody, induced a prothrombotic state in the mice by inducing tissue factor expression upon circulating monocytes, resulting in thrombus formation at the site of laser-induced endothelial injury. This diathesis was almost completely ameliorated by DHMEQ treatment.


Inhibition of the NF-κB pathway is a promising strategy for the development of a novel treatment for APS.


Antiphospholipid syndrome; NF-kappa B; Thrombosis; Tissue factor

Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk